OGA and tauopathy: The possible dynamic interplay between protein O-GlcNAcylation and phosphorylation has led to the hypothesis that inhibition of the OGA enzyme would promote O-GlcNAcylation of tau, thereby attenuating tau hyperphosphorylation and providing therapeutic benefit for AD and other tauopathies [6].